GEORGETOWN LAW. Georgetown University Law Center. CIS-No.: 2007-S521-52

Similar documents
THE AMERICA INVENTS ACT NEW POST-ISSUANCE PATENT OFFICE PROCEEDINGS

Issues and Possible Reforms in the U.S. Patent System

Statement of. Hon. General J. Mossinghoff Senior Counsel Oblon, Spivak, McClelland, Maier & Neustadt, P.C. before the

Raising the Stakes in Patent Cases

What is Intellectual Property?

Public Hearings Concerning the Evolving Intellectual Property Marketplace

Litigators for Innovators

Algae Biomass Summit 2014: Patent Strategies for Algae Companies in an Era of Patent Reform Peter A. Jackman, Esq. October 2, 2014

Judicial System in Japan (IP-related case)

IP Infringement Enforcement Strategies China

Vistas International Internship Program

Key Strategies for Your IP Portfolio

IP Outlook in the Reform Era

MPEP Breakdown Course

Carnegie Endowment for International Peace

The Uneasy Future of Software and Business-Method Patents

How To Draft Patents For Future Portfolio Growth

WIPO REGIONAL SEMINAR ON SUPPORT SERVICES FOR INVENTORS, VALUATION AND COMMERCIALIZATION OF INVENTIONS AND RESEARCH RESULTS

Patent Masters Symposium A part of the IPWatchdog Institute

Key issues in building a strong life sciences patent portfolio. Tom Harding and Jane Wainwright Potter Clarkson LLP

Invention SUBMISSION BROCHURE PLEASE READ THE FOLLOWING BEFORE SUBMITTING YOUR INVENTION

Why patents DO matter to YOUR business

International Patent Exhaustion

Statement by the BIAC Committee on Technology and Industry on THE IMPACT OF INTELLECTUAL PROPERTY PROTECTION ON INNOVATION AND TECHNOLOGY DEVELOPMENT

The America Invents Act: Policy Rationales. Arti K. Rai Duke Patent Law Institute May 13, 2013

Parliamentary Research Branch PATENT DEDICATION AND THE PATENTED MEDICINE PRICES REVIEW BOARD. Margaret Smith Law and Government Division

ARE PATENTS REALLY LIMITED TO 20 YEARS? A CLOSER LOOK AT PHARMACEUTICALS. Melody Wirz. I. Introduction

China: Managing the IP Lifecycle 2018/2019

Documentation of Inventions

Intellectual Property Rights at the JPO: Statistics (2017)

UNITED STATES OF AMERICA BEFORE THE FEDERAL ENERGY REGULATORY COMMISSION

Post-Grant Review in Japan

THE LEGAL MARKETPLACE IN AN EVOLVING PATENT LANDSCAPE

Patent. Highlights 2012 Understanding US Patent Reform and What it Means to Your Business. Madrid, 11 June 2012 Barcelona, 12 June 2012

11th Annual Patent Law Institute

Pergamon Corporation CONFRENCE

PATENT PROTECTION FOR PHARMACEUTICAL PRODUCTS IN CANADA CHRONOLOGY OF SIGNIFICANT EVENTS

Your SBIR Data Rights and How to Protect Them

CRS Report for Congress

Maximizing IP Value in an Economic Downturn

Developing Countries in the Globalization of Pharmaceutical Patenting

From the Experts: Ten Tips to Save Costs in Patent Litigation

11th Annual Patent Law Institute

Empirical Research on Invalidation Request of Invention Patent Infringement Cases in Shanghai

5 Ways To Ramp Up Your Patent Portfolio

PROBLEMS TO BE EXPECTED FROM EXPANDED ADMINISTRATIVE CHALLENGES TO U.S. PATENTS

Patent Law: What Anesthesiologists Should Know

Slide 15 The "social contract" implicit in the patent system

Introduction to IP: Some Basics of Patents, Trademarks, & Trade Secrets

Intellectual Property

Protecting Your Innovations and IP. Dr. Matthias Nobbe German and European Patent Attorney European Trademark and Design Attorney

Litigation Funding for Patent Disputes

INVENTION LAW OF THE DEMOCRATIC PEOPLE S REPUBLIC OF KOREA. Chapter 1 Fundamentals

UNITED STATES INTERNATIONAL TRADE COMMISSION WASHINGTON, DC 20436

From invention to market with PatronUS ip

Network-1 Technologies, Inc.

Coase 2.0 and the Patent System Why Policy Makers Need To Focus on the Information Sharing Incentives and Mechanisms in Patent Law.

2012 Annual Convention

Google reveal. their secret to a successful IP Litigation strategy. Catherine Lacavera, Director of IP and Litgation, Google

Reexamination: A Viable Alternative to Patent. Litigation?? Dale L. Carlson and Jason Crain??

Network-1 Technologies, Inc.

First to Invent vs. First to File: The Impact of an Old Dilemma on the Future of Biotechnology and Pharmaceutical Discoveries

Research Collection. Comment on Henkel, J. and F. Jell "Alternative motives to file for patents: profiting from pendency and publication.

Why patents DO matter to YOUR business

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE CODING SYSTEM FOR REDUCING REDUNDANCY ATTACHMENT TO FORM PTO-1465, REQUEST FOR EX PARTE REEXAMINATION

THE UNIVERSITY OF AUCKLAND INTELLECTUAL PROPERTY CREATED BY STAFF AND STUDENTS POLICY Organisation & Governance

Statement of Robert A. Armitage Senior Vice President and General Counsel Eli Lilly and Company, Indianapolis, Indiana. Before

Mr. Chairman and Members of the Subcommittee:

The role of Intellectual Property (IP) in R&D-based companies: Setting the context of the relative importance and Management of IP

Utility Utilit Model Sy Model S stem in China

INTELLECTUAL PROPERTY LITIGATION

WIN In-House Counsel Day Melbourne

Paper No Entered: November 6, 2015 UNITED STATES PATENT AND TRADEMARK OFFICE

Protect your ideas. An introduction to patents for students of natural sciences, engineering, medicine and business administration

Patenting Strategies. The First Steps. Patenting Strategies / Bernhard Nussbaumer, 12/17/2009 1

Patent Masters Symposium A part of the IPWatchdog Institute

McRO Syncs Automation Software With Patent Eligibility

Patent Purchase Information of Seller

Tiffany D. Gehrke. Associate. Tel

Advocates of Innovation

Observations from Pharma

Bioengineers as Patent Attorneys: Analysis of Bioengineer Involvement in the Patent Writing Process

California State University, Northridge Policy Statement on Inventions and Patents

THE AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION RECOMMENDATIONS REGARDING QUALIFICATIONS FOR

Overview of Intellectual Property Policy and Law of China in 2017

IS STANDARDIZATION FOR AUTONOMOUS CARS AROUND THE CORNER? By Shervin Pishevar

Patents in Europe 2018/2019. Helping business compete in the global economy. Litigating patents under the UPC system

SAMPLE DOCUMENT. Date: 2014 USE STATEMENT & COPYRIGHT NOTICE

Clarity of thought: telling Congress how to improve 101

The 9 Sources of Innovation: Which to Use?

Lewis-Clark State College No Date 2/87 Rev. Policy and Procedures Manual Page 1 of 7

Larry R. Laycock. Education. Practice Focus. Attorney at Law Shareholder

Does the US Patent System Need a Patent Small Claims Proceeding?

AusBiotech response to Paper 1: Amending inventive step requirements for Australian patents (August 2017)

Comments on Public Consultation on Proposed Changes to Singapore's Registered Designs Regime

WIPO LIST OF NEUTRALS BIOGRAPHICAL DATA

User Rights in Patent Law. Ofer Tur-Sinai IPSC, August 2011

Intellectual Property and Sustainable Development

Practical Strategies for Biotechnology and Medical Device Companies to Manage Intellectual Property Rights

Ways to Maximize Your Intellectual Property Assets

Transcription:

Georgetown University Law Center Scholarship @ GEORGETOWN LAW 2006 Perspectives on Patents: Post-Grant Review Procedures and Other Litigation Reforms: Hearing Before the Subcomm. on Intellectual Property of the S. Comm. on the Judiciary, 109th Cong., May 23, 2006 (Statement of Professor John R. Thomas, Geo. U. L. Center) John R. Thomas Georgetown University Law Center, jrt6@law.georgetown.edu CIS-No.: 2007-S521-52 This paper can be downloaded free of charge from: http://scholarship.law.georgetown.edu/cong/32 This open-access article is brought to you by the Georgetown Law Library. Posted with permission of the author. Follow this and additional works at: http://scholarship.law.georgetown.edu/cong Part of the Administrative Law Commons, and the Intellectual Property Commons

Testimony of John R. Thomas Professor, Georgetown University Law Center Hearing: Patent Review May 23, 2006 U.S. Senate Judiciary Committee Subcommittee on Intellectual Property

May 23, 2006 Thank you for the opportunity to testify before the Committee on the subject of postgrant review procedures. I appear today on my own behalf, as a concerned observer of the patent system. Current patent reform efforts have been accompanied by an often heated exchange of views concerning a range of subjects. Despite their differences on other issues, however, many observers agree that our current administrative revocation procedures have been unsuccessful ventures. Limited use of both ex parte and inter partes reexamination procedures have placed both procedures in a state of desuetude. Many actors in the technology community view more full-fledged opposition procedures as the best means for harnessing the expertise of the PTO to assess the validity of issued patents. Opinions differ, however, concerning many of the important details of opposition procedures. In their efforts to establish an effective opposition system, patent reformers would do well to identify clearly its intended goals. Some observers view oppositions as a rather cabined curative proceeding that would effectively serve as the final stage of patent acquisition procedures. Others view oppositions as low-cost litigation substitutes that potentially provide a way to improve quality throughout the nation's entire portfolio of issued patents. In addition, in a world where technology knows no borders, we may wish our opposition procedure to reflect international norms, thereby serving the laudable goal of patent harmonization. Although these policy goals are not mutually exclusive, the precise contours of an opposition system follow from those that are selected or emphasized. Allow me to address three aspects of opposition proceedings under current discussion. One is whether the availability of oppositions should be subject to time limits. As with the European Patent Convention, current proposals before the House of Representatives provide for a nine-month period. Debate has proceeded upon whether legislation should call for a six-month second window for initiation of an opposition proceeding, based 2

upon receipt of a charge of patent infringement. Imposing time limits on oppositions has been justified upon notions of stability of the property right. Further exploration of this view is appropriate. First, the nine-month European deadline is not an absolute one, in the sense that nullity trials and similar options remain available under the national laws of European Patent Convention signatory states. In the United States, the Patent Act places no time limit upon commencing a reexamination. Similarly, under the reissue statute, patent proprietors themselves possess the ability to amend their claims at any time during the life of the patent. Time limits may also be motivated by a desire to avoid harassment of patentees. Interestingly, experience with the German patent system suggests that such restrictions may have the opposite effect. The German law once imposed a five-year deadline upon contesting validity of a patent. Observing that many such challenges occurred on the eve of the deadline, the time restrictions were ultimately eliminated-reportedly resulting in a measurable decrease in the number of oppositions filed. Strict time limits may also detract from the ability of an opposition to serve as a prompt, inexpensive mechanism for assessing a patent's validity. Patents often issue long before the inventions they claim become commercially viable. For example, at the time a patent claiming a pharmaceutical or medical device issues from the PTO, its proprietor may remain engaged in the FDA marketing approval process. Other patents are sold to new owners with more aggressive enforcement postures; still others are simply ahead of their time. Requiring potential patent challengers to provoke oppositions early in a patent's term may lead to ill-informed decisions, to the detriment of patent owners and the public alike. As a result, debate over time limits may properly center not upon whether a sixmonth second window is justified, but rather upon whether time limits can be justified at all. Second, following the lead of Professor Mark Janis, I encourage the Committee to 3

recognize that the trademark law has for many years allowed for both a pre-grant opposition and a post-grant cancellation procedure. In this context, the PTO has promulgated rules that incorporate such features as an extensive motions practice, hearings, and discovery, including interrogatories, document production, and depositions. I do not wish merely to offer the naive suggestion that trademark inter partes procedures could simply be adopted wholesale into a patent opposition system. Yet the PTO's considerable experience with inter partes proceedings in the context of trademarks should both assuage concerns over its institutional competence, and provide valuable guidance for patent opposition procedures. Last, I would encourage the Committee to consider the public goods problems that accompany patent oppositions. No matter how refined the contours of an opposition system are, individuals may possess limited incentives to employ them. The reason, of course, is the general rule that a patent is valid or invalid as to all the world. A firm that prevails in a patent opposition must share its success with its marketplace competitors. This forced sharing may, of course, lead to a suboptimal level of patent challenges. The Hatch-Waxman Act incorporated a 180-day generic exclusivity period in order to address this public goods problem; similar attention in the context of patent oppositions may ultimately increase their effectiveness. Thank you for the opportunity to testify before you today. I would be pleased to answer any questions. 4